Navigation Links
Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
Date:7/30/2008

effect over the human genome as the lower-dose resveratrol when provided in a matrix of other mineral-chelating natural molecules.

The discovery was made utilizing laser scanning technology to measure levels of messenger-RNA from thousands of genes in tissues obtained from test animals. Researchers used a commercially available GeneChip(R) (Affymetrix), which is about the size of a credit card.

Mice and humans share about 99% of their 30,000 genes. Most gene expression changes caused by aging are partially or completely prevented by CR. This discovery is suggestive of a day when humans could molecularly avert the effects of over-eating as well as slow or even reverse the aging process without having to deprive themselves of food.

A life-long CR diet is anticipated to influence more than the 200 genes shown in this short-term study, but the nutriceutical matrix exerted influence much sooner, raising the possibility that adherence long-term CR may not be required to obtain the same benefits.

The study was sponsored by Resveratrol Partners LLC, maker of Longevinex(R), a patent-applied-for nutriceutical (http://www.longevinex.com).

Resveratrol Partners LLC is a privately held Nevada limited liability company that markets its unique nutriceutical dietary supplement solely under the LONGEVINEX(R) trade name. Google has chosen to affix the stock symbol of another unrelated company to their GOOGLE NEWS listing for this press release, but Resveratrol Partners LLC, dba LONGEVINEX(R) has no affiliation with that or any other company.


'/>"/>
SOURCE Longevinex(R)
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3

Related medicine technology :

1. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
2. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
3. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
4. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
5. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
8. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
9. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
10. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
11. Video: New Research Discovers Independent Brain Networks Control Human Walking

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/7/2009).... 7 Patients reported C1-esterase ...rapy in treating acute swelling attacks at any bod...order, according to data presented today at the 20...ology (ACAAI) Annual Meeting. The results come fro...parallel with the ongoing, prospective, open label...
(Date:11/6/2009)... SCOLR Pharma, Inc. (Ame... three and nine months ended September 30, 2009. ... and CEO, said, "We continue to advance discussion...lation. Several potential partners have committed ...nal resources as they evaluate the potential comme...
(Date:11/6/2009)...ewswire-FirstCall/ -- Recession in domestic and in... Allied Healthcare Products in the first quarter o..., Sales declines pushed Allied into a loss for the...$745,000, or negative 9 cents per share, compared ..., or 3 cents per share. ,, Sales fell about 21...
Breaking Medicine Technology:Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 55567 1Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 55567 2Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 55567 3Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 55567 4Fat Fighting Chemical Holds Promise 55564 1Fat Fighting Chemical Holds Promise 55564 2ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 1ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 2ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 3ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 4ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 5ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 6ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 7ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 8ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 9ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 10ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 11ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 12ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 13ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 14ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 15
...hKline (NYSE: GSK ),announced positive safety an...,controlled ITP Study with Eltrombopag), a Phase I...th chronic immune (idiopathic) thrombocytopenic,pu... therapies. Patients,receiving PROMACTA were eight...in platelet counts between 50,000 to 400,000/micro...
...he Local Treatment of Oral Candidiasis in Immunosu...J., Dec. 5 RHEI Pharmaceuticals, Inc. today annou... locally active antifungal with low dose miconazol...iated in China. This will be the last clinical tr...cation (NDA) to the State Food and Drug Administra...
Other Medicine Technology:GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 2GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 3GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 4GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 5GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 6GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 7GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 8RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China 2
(Date:11/9/2009)...t of seniors have changed Medicare plans, 16 perce...nd improved coverage among biggest drivers ,to cha... Belleville, Il (Vocus) No...have changed their Medicare plan since becoming el...ey are likely to or are considering switching plan...
(Date:11/9/2009)...for breast cancer are at higher risk of cancer rec...he December 15, 2009 issue of Cancer , a peer-rev...study,s results indicate that breast cancer patien...therapies following surgery, such as radiation. ,...breast tissue are at increased risk of breast canc...
(Date:11/8/2009)...USNewswire/ -- The American Public Health Associat...ovisions in the health reform bill passed last nig... the House takes important steps toward universal ...nd moving our health system from one that focuses ...g people healthy," said Georges C. Benjamin, MD, F...
(Date:11/8/2009)...ail Nation,s Job Creators ,, WASHINGTON, Nov. 8...use passage of the health care bill (H.R. 3962), S...Council) president & CEO Karen Kerrigan issued... those voting for H.R. 3962 voted to burden our na... taxes and penalties. Even in the best of economic...
(Date:11/8/2009)... of biopharmaceuticals to be available at the Comp... Toronto, ON (PRWEB) November ...erapure Biopharma Inc. today announced that the Co...rmaceutical grade freeze dryer and expects to make...vailable for contract manufacturing of biopharmace...
Breaking Medicine News(10 mins):Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 2Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 3Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 4Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 5Health News:Breast density associated with increased risk of cancer recurrence 2Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2
...tes call on Congress to pass meaningful health ref...on , , WASHINGTON, April 21 With millions of Am... insurance and health care, heart and stroke survi...th their representatives for the American Heart As...
...itute is pleased to welcome Tevi Troy, most recent...d Human Services (HHS) under George W. Bush, as a ...will write on health care, medical innovation, and...ining Hudson at this important juncture," says Hud...
... violence in urban communities show symptoms of po...l effects with a disruption to their normal cortis...ve long-term negative effects on their health. Acc...spital, Harvard Medical School in Boston, USA, bec...
..., , MONMOUTH JUNCTION, N.J., April 21 Transave, ...ent in a Phase II study evaluating the safety and ...inhalation) in non-cystic fibrosis (CF) bronchiect... Presently, there are no approved treatments for t...
...he latest series of wall-mounted diagnostic imagin... attractive covering , , NILES, Ill., April 21 M... images for more than three decades, introduces th...t created a new term when it became the industry,s...
...tronics, Inc. will enhance its Clinical Conductor(...rough integration to Interspond,s RxPaying(TM) deb...yment alternative which improves efficiency and in...ise can be integrated seamlessly. Dan Kerpelman, P...
Other Medicine News:Health News:Healthcare Reform Tops Agenda for Hundreds of Heart Disease and Stroke Survivors on Capitol Hill 2Health News:Former HHS Deputy Secretary Tevi Troy Joins Hudson Institute 2Health News:Witnessing violence affects kids' health 2Health News:Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study 2Health News:Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study 3Health News:MAXANT Launches MediPort 3000, The Next-Generation of All-In-One Workstations, on Its Newly Designed Website 2Health News:Bio-Optronics Incorporates RxPaying(TM) Patient Stipend Debit Card Feature in Clinical Conductor(TM) Clinical Trial Management System (CTMS) 2
Centrifuge 4-15C *Avaiable in Europe and Australia*
Centrifuge 4-15C *Available in Japan*
...khorse for the lab, featuring easy-to-use control ...ce. , Product features , , Digital display ... (W x D) footprint fits on a crowded bench, or in ...motor provides maintenance-free operation , Spi...
...Hz, 100/120 V Fast - Powerful g-Force for Fast a...s up to 14,000 rpm (18,000 x g) Ideal for pelleti... Fits on crowded bench or in a cold room Come...able fixed-angle rotor Quiet operation ≤ 58...
Medicine Products: